New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2014
09:18 EDTTEVA, PATHTeva completes tender offer for NuPathe shares
Teva (TEVA) announced the completion of the tender offer by Train Merger Sub, a wholly-owned subsidiary of Teva, for all of the outstanding shares of common stock of NuPathe (PATH) at a price of $3.65 per share in cash and the right to receive contingent cash consideration payments of up to $3.15 per share, net to the seller in cash without interest. The offer expired on February 20 and was not extended. The depositary for the offer has advised Teva that a total of 28,178,652 shares were validly tendered into and not validly withdrawn from the Offer representing approximately 80.01255%% of NuPathe’s outstanding shares. Upon completion of the merger, NuPathe will become a wholly-owned subsidiary of Teva. In the merger, each share of NuPathe that was not validly tendered in the offer will be canceled and converted into the right to receive the same $3.65 per share in cash and the right to receive contingent cash consideration payments of up to $3.15 per share, without interest, that was paid in the offer. It is expected that the common stock of NuPathe will cease to be traded on NASDAQ at the close of market on February 20 following completion of the merger.
News For TEVA;PATH From The Last 14 Days
Check below for free stories on TEVA;PATH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
08:11 EDTTEVAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
08:01 EDTTEVATeva completes acquisition of Labrys
Subscribe for More Information
July 16, 2014
08:48 EDTTEVATeva says ISS supports company's nominees, shareholders' meeting proposals
Subscribe for More Information
July 15, 2014
11:13 EDTTEVAPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
06:28 EDTTEVAActivist shareholder says Teva to appoint new chairman, Reuters says
Subscribe for More Information
July 14, 2014
08:04 EDTTEVATeva announces FDA acceptance of NDA filing for albuterol MDPI
Teva Pharmaceuticals Industries announced that the U.S. Food and Drug Administration has accepted for review the company’s new drug application for albuterol multi-dose dry-powder inhaler, an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. The NDA filing includes data from eight clinical studies that evaluated the safety and efficacy of albuterol MDPI in adults and adolescents with asthma and exercise-induced bronchospasm. The NDA for albuterol MDPI has been accepted by the FDA for standard review, with a FDA Regulatory Action expected in March 2015.
July 9, 2014
07:15 EDTTEVATeva, others fined $583.4M by EU regulators, Reuters says
Subscribe for More Information
06:49 EDTTEVAGeneric drug prices have risen significantly, NY Times says
Subscribe for More Information
July 8, 2014
07:03 EDTTEVAEagle Pharmaceuticals receives orphan drug designation for bendamustine HCl
Eagle Pharmaceuticals (EGRX) announced that the FDA has granted orphan drug designation to bendamustine hydrochloride, a ready-to-dilute concentrate solution for injection that will be administered by infusion over 10 minutes after dilution in 50mL of sodium chloride or a saline / dextrose mixture, for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. Pursuant to the orphan drug designation, Eagle is eligible to receive tax incentives and Prescription Drug User Fee Act fee savings, and believes it may receive seven years of marketing exclusivity. The currently marketed bendamustine HCI product, Treanda, which is manufactured by Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries (TEVA), is a lyophilized powder requiring reconstitution and dilution in 500mL of saline or a sodium chloride / dextrose mixture before administration over 30 minutes for CLL and 60 minutes for NHL.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use